| Bioactivity | YM440 is an orally active oxadiazolidinedione analog. YM440 ameliorates hyperglycemia without changing PPARy activity, adipocyte differentiation, or fat weight. YM440 is used in the study for non-insulin-dependent diabetes mellitus (NIDDM)[1]. |
| In Vivo | YM440 (100 mg/kg，口服，每天一次，持续28天，db/db小鼠) 增加了肝脏葡萄糖激酶的表达，但未增加脂肪组织 FABP 和 UCP1 的表达，这表明 PPARγ 相关基因在组织中具有选择性表达。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| CAS | 163300-58-1 |
| Formula | C22H20N4O8 |
| Molar Mass | 468.42 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. A Shimaya, et al. The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice. Metabolism. 2000 Mar;49(3):411-7. [2]. Eiji Kurosaki, et al. Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation. Biochem Pharmacol. 2003 Mar 1;65(5):795-805. |